● pepmg Research Desk · Peer-reviewed evidence review
What the research says about vesugen
A neutral summary of the peer-reviewed literature on vesugen, a synthetic Lys-Glu-Asp tripeptide bioregulator studied almost entirely by a single research lineage in animal and in-vitro models, with one small uncontrolled human observational study and no controlled human trials. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Vesugen is described in the literature as a synthetic tripeptide with the sequence Lys-Glu-Asp, in the family of Khavinson-type short peptide bioregulators, studied in the context of vascular tissue [4].
- The evidence is almost entirely preclinical: animal and in-vitro studies report antihypoxic effects, tissue-specific stimulation of differentiation markers in human-cell cultures, and effects on a proliferation marker in vascular endothelial cells [1][2][4][5].
- A single small, uncontrolled human observational study (32 people) reported effects it framed as anti-aging alongside signals the authors themselves flagged as concerning, including inhibition of blood-cell formation and prooxidant activity; there are no controlled human trials [6].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What vesugen is
Vesugen is characterized in the literature as a synthetic tripeptide with the sequence Lys-Glu-Asp, one of a family of Khavinson-type short peptide bioregulators reported to act tissue-specifically in cell culture, with vesugen studied in the context of vascular tissue [4]. In one study it was described as stimulating differentiation markers specifically in fibroblasts, in contrast to related peptides that acted on pancreatic or bronchial cells [4].
Vesugen is a research compound, not an approved medicine. Material sold by third-party research-chemical vendors is offered for laboratory and research use only.
What the research has measured
Preclinical onlyMost of the evidence for vesugen is preclinical. In a hypobaric-hypoxia animal model, vesugen was among short regulatory peptides reported to show antihypoxic properties, though the authors described a related peptide (pinealon) as having the most pronounced effect of those tested [1]. In in-vitro model experiments, vesugen was among short peptides reported not to show direct antioxidant activity but to restrict lipid peroxidation of human lipoproteins and to increase the stability of red-blood-cell membranes against osmotic hemolysis [2].
Other work measured differentiation and proliferation endpoints. In organotypic culture of pineal lymphoid tissue, the tripeptide vesugen was reported to have no effect on the differentiation capacity of the immune cells but to enhance their proliferation potential, in contrast to other peptides that shifted differentiation [3]. In cultures of aging human prostatic fibroblasts, vesugen (Lys-Glu-Asp) was reported to tissue-specifically stimulate the expression of differentiation factors, with the effect described as more pronounced in aged cultures [4].
One animal study proposed a mechanism for a vascular effect. In tissue-specific and dissociated vascular-endothelial-cell cultures, vesugen was reported to stimulate the proliferation-associated protein Ki-67 (which declines with aging), and a molecular-docking analysis suggested an interaction with the promoter region of the Ki-67 gene; the authors framed this as a possible epigenetic basis for a vasoprotective effect they described as previously observed in elderly people [5]. That prior human observation is the small uncontrolled study discussed below.
What the human study and the preclinical work report on safety
Preclinical onlyThere are no controlled human trials of vesugen. One small, uncontrolled human observational study administered vesugen (and a comparator peptide, pinealon) to 32 people aged 41 to 83 with chronic polymorbidity and organic brain syndrome in remission [6]. The authors reported effects they framed as anabolic and anti-aging, but they also reported signals they flagged as concerning: a prooxidant effect by chemiluminescence and a decrease in circulating CD34-positive hematopoietic cells that they described as significant inhibition of blood-cell formation [6]. They noted that vesugen did not affect the degree of chromatin condensation and described this as safe at the nuclear-genetic level, while stating the effect should be studied further [6]. This is a small, uncontrolled study reporting its own author-flagged caveats, not a demonstration of safety.
The preclinical abstracts describe measured biological effects rather than a formal toxicity profile, reporting endpoints such as antihypoxic activity, membrane stability, and stimulation of a proliferation marker [1][2][5]. These are measured effects in animal and cell models, not a human safety characterization, and the abstracts do not report toxicity testing.
Because the human data are limited to one small uncontrolled study and the rest are preclinical, nothing here should be read as a safety statement for people. Material sold by research-chemical vendors is not a regulated medicine. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence for vesugen is characterized as preclinical: it consists of animal and in-vitro studies (antihypoxia, lipoprotein and membrane assays, differentiation and proliferation markers, and a molecular-docking analysis), plus a single small, uncontrolled human observational study whose own authors flagged prooxidant activity and inhibition of blood-cell formation [1][2][5][6]. There are no controlled human trials, and the literature is drawn essentially from a single research lineage. "Preclinical" describes the design and scope of the published studies, not an endorsement; the one human study is small, uncontrolled, and reports mixed and author-flagged findings rather than a controlled outcome.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 6
- [Investigation of antihypoxic properties of short peptides].
- [Biological activity of regulatory peptides in model experiments in vitro].
- Peptidegic stimulation of differentiation of pineal immune cells.
- Peptides tissue-specifically stimulate cell differentiation during their aging.
- [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging].
- [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission].
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.